(Bloomberg) -- Since 2012, an increasing number of drugs have been approved by U.S. regulators through programs meant to speed them to market.
It’s good news for patients who benefit sooner from potentially life-saving treatments.
The downside, a government watchdog agency said Thursday, is that the Food and Drug Administration hasn’t been keeping up with monitoring what happens after the drugs are being prescribed to patients--as it should.
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to asset-and-logo-licensing@alm.com. For more information visit Asset & Logo Licensing.
